The palliation of hepatic metastases: Results of the radiation therapy oncology group pilot study

doi:10.1016/0360-3016(81)90370-9

International Journal of Radiation OncologyBiologyPhysics

Volume 7, Issue 5, May 1981, Pages 587-591

https://doi.org/10.1016/0360-3016(81)90370-9 Get rights and content

Abstract

From May, 1976, to July, 1978, 20 Radiation Therapy Oncology Group (RTOG) institutions participated in a prospective, uncontrolled, non-randomized pilot study designed to gain information regarding the feasibility of hepatic irradiation for the treatment of symptomatic liver metastases. One hundred-three of 109 patients who entered were included in the present analysis. Eligible patients included those with hepatic metastases from solid, non-hematologic tumors documented by liver scan. Patients with solitary liver metastases received either 3040 rad/19 fractions or 3000 rad/15 fractions followed by an optional 2000 rad/10 fractions boost to residual disease. Those with a solitary hepatic metastasis plus other sites of metastases or with multiple hepatic metastases received 3000 rad/15 fractions, 2560 rad/16 fractions, 2000 rad/10 fractions or 2100 rad/7 fractions. Seventy-four percent completed the planned course of treatment. Nausea and/or vomiting was induced or aggravated in 16%. There were no documented cases of radiation-induced hepatitis, nephritis or pneumonitis. The degree of symptom improvement ranged from 19 % (weakness/fatigue) to 55 % (pain). Improvement of liver function chemistries occurred in 40 % and palpable liver mass was reduced in 49%. Performance status improved in 25% of patients. The overall median survival of patients who died is 11 weeks. The results of this study indicate that rapid courses of whole liver irradiation are well-tolerated with good therapeutic benefit in patients with symptomatic liver metastases. Additional studies are being developed by the RTOG to investigate combined modality approaches for the palliation of patients with hepatic metastases.

References (15)

B. Prasad et al.
Irradiation of hepatic metastases
Int. J. Radiat. Oncol. Biol. Phys.
(1977)
H.W. Whiteley
Radiation therapy in the palliative management of patients with recurrent cancer of the rectum and colon
Surg. Clinic N. Am.
(1969)
J.H. Foster
Survival after liver resection for cancer
Cancer
(1970)
J.A. Ingold et al.
Radiation hepatitis
Am. J. Roentgenol.
(1965)
B.M. Jaffe et al.
Factors influencing survival in patients with untreated hepatic metastases
Surg. Gynecol. Obstet.
(1968)
H.S. Kaplan et al.
Radiation hepatitis: Possible prevention by combined isotopic and external radiation therapy
Radiology
(1968)
D.A. Karnofsky
Experimental cancer chemotherapy

There are more references available in the full text version of this article.

Cited by (144)

Use of Radiotherapy in Advanced Breast Cancer: The Role of a Nurse
2024, Seminars in Oncology Nursing
Systemic therapy is the mainstay in advanced breast cancer (ABC), but innovations in radiation oncology have given radiotherapy a crucial role in the treatment of both intracranial and extracranial ABC. Breast cancer specialists include, in addition to medical and clinical oncologists, breast cancer nurses with unique theoretical knowledge and significant clinical experience. This review aims to discuss the function of radiotherapy in ABC and to highlight the role and importance of specialized nursing care for ABC patients receiving radiotherapy.
An extensive literature review was conducted on the role of radiotherapy and its implementation in various settings of ABC and the pivotal contribution of nursing practices to the quality of life of these patients, with a particular focus on symptom and side effect management and prevention, education, as well as unmet patient needs. The Advanced Breast Cancer International Consensus Guidelines (ABC-5) were also included. All the above data were combined with the expert and practical considerations of breast cancer specialists within the team.
The sophisticated application of radiotherapy and the complexity of ABC patient management, concerning symptoms, side effects, and overall well-being necessitate collaborative efforts to optimize patient care. Breast cancer nurses hold a central role in this framework.
The significance of specialized nursing in contributing to comprehensive patient care for ABC patients treated with radiotherapy outlines the need for extensive training that aims to provide a holistic approach and entails physical, mental, and emotional support and patient and caregiver education.
Combination treatment of HCC with SBRT and immune checkpoint inhibition
2023, Critical Reviews in Oncology/Hematology
The treatment of unresectable or metastatic HCC has been significantly advanced in recent years by developments in both radiotherapy and systemic cancer therapies. Independently, both Stereotactic Ablative Body Radiotherapy (SBRT) and Immune Checkpoint Inhibitors (ICIs) are licensed for the treatment of these tumours. Building on the successes seen in other solid tumours, there is significant interest in exploring combination treatments. In this review article we briefly present the evidence base for the use of these treatments in patients with HCC. With reference to our current understanding of the immuno-oncology and radiobiology of HCCs, we demonstrate why combining these two modalities is of interest. Finally, we discuss the clinical trials that are currently underway or planned and the direction that future research may take.
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity
2022, JHEP Reports
Hepatocellular carcinoma (HCC) accounts for 90% of liver tumours and is one of the leading causes of mortality. Cirrhosis due to viral hepatitis, alcohol or steatohepatitis is the major risk factor, while liver dysfunction due to cirrhosis is a deciding factor in its treatment. The treatment modalities for HCC include liver transplant, hepatectomy, radiofrequency ablation, transarterial chemoembolisation, transarterial radioembolisation, targeted therapy, immunotherapy, and radiation therapy. The role of radiation therapy has been refined with the increasing use of stereotactic body radiation therapy (SBRT). Trials over the past two decades have shown the efficacy and safety of SBRT in recurrent and definitive HCC, leading to its acceptance and adoption in some more recent guidelines. However, high quality level I evidence supporting its use is currently lacking. Smaller randomised trials of external beam radiation therapy suggest high efficacy of radiation therapy compared to other treatments for patients with unresectable HCC, and phase III trials comparing SBRT with other modalities are ongoing. In this review, we discuss the rationale for SBRT in HCC and present evidence on its efficacy, associated toxicity, and technological advances.
Hepatic tumours and radiotherapy
2022, Cancer/Radiotherapie
We present the update of the recommendations of the French society of oncological radiotherapy on hepatic tumours. Recent technological progress led to develop the concept of focused liver radiation therapy. We must distinguish primary and secondary tumours, as the indications are restricted and must be discussed as an alternative to surgical or medical treatments. The tumour volume, its liver location close to the organs at risk determine the irradiation technique (repositioning method, total dose delivered, dose fractionation regimens). Tumour (and liver) breathing related motions should be taken into account. Strict dosimetric criteria must be observed with particular attention to the dose–volume histograms of non-tumoral liver as well as of the hollow organs, particularly in case of hypofractionated high dose radiotherapy “under stereotaxic conditions”. Stereotactic body radiotherapy is being evaluated and is often preferred to radiofrequency for primary or secondary tumours (usually less than 5 cm). An adaptation can be proposed, with a conformal fractionated irradiation protocol with or without intensity modulation, for hepatocellular carcinomas larger than 5 cm.
Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique sur la radiothérapie des tumeurs hépatiques. Les évolutions technologiques récentes ont permis de développer le concept de « radiothérapie hépatique focalisée ». Il convient de distinguer les tumeurs primitives de celles secondaires car les indications peuvent être différentes et doivent être discutées en alternative aux traitements chirurgicaux ou médicaux. Le volume tumoral, sa position dans le foie et par rapport aux organes à risque conditionnent la technique d’irradiation (méthode de repositionnement, dose totale délivrée, dose par séance et étalement). Les mouvements de la tumeur (et du foie) liés à la respiration doivent être pris en compte. Il faut respecter des critères dosimétriques stricts avec une attention toute particulière sur les histogrammes dose–volume du foie non tumoral ainsi que des organes creux, notamment en cas de radiothérapie hypofractionnée de haute dose dite « en conditions stéréotaxiques ». Cette radiothérapie en conditions stéréotaxiques est en cours d’évaluation et est souvent préférée à la radiofréquence pour les tumeurs primitives ou secondaires (en général de moins de 5 cm). Une adaptation peut être proposée, avec un protocole d’irradiation fractionnée conformationnelle avec ou sans modulation d’intensité, pour les carcinomes hépatocellulaires de plus de 5 cm.
Chronic cancer pain syndromes and their treatment
2022, Neurological Complications of Systemic Cancer and Antineoplastic Therapy
Pain is one of the most common symptoms experienced by cancer patients, and pain can affect patients at presentation and is even more prevalent in advanced stages. Controlling cancer-related pain is critical to preserving patient quality of life. Bone metastases and related pain are the most common chronic pain syndrome in cancer patients, often secondary to lung, breast, and prostate cancers. Other common types of chronic cancer pain are related to organ metastases, headache, facial pain, nerve damage and related types of neuropathic pain, and paraneoplastic nociceptive syndromes. In addition, there are numerous chronic pain syndromes that can arise secondary to cancer treatment, including surgical intervention, radiotherapy, and chemotherapy. This chapter will review all of these chronic cancer pain syndromes, as well as discuss various types of intervention to relieve cancer pain.
Use of Multi-Site Radiation Therapy for Systemic Disease Control
2021, International Journal of Radiation Oncology Biology Physics
Citation Excerpt :
Although toxicities related to low-dose irradiation of large tumor volumes is yet to be defined, prior studies examining lower-dose irradiation of large tumors volumes may offer insight. For example, conventionally fractionated whole liver irradiation (range, 17-30 Gy) is relatively safe with complication rates of less than 16%.83-85 Our understanding of the extent to which we can safely irradiate lesions is still somewhat limited, in that little information is available as to whether it is better to irradiate a few lesions, most lesions, or all lesions to prompt adequate release of antigens or TILs or to appropriately overcome the tumor stroma.
Metastatic cancer is a heterogeneous entity, some of which could benefit from local consolidative radiation therapy (RT). Although randomized evidence is growing in support of using RT for oligometastatic disease, a highly active area of investigation relates to whether RT could benefit patients with polymetastatic disease. This article highlights the preclinical and clinical rationale for using RT for polymetastatic disease, proposes an exploratory framework for selecting patients best suited for these types of treatments, and briefly reviews potential challenges. The goal of this hypothesis-generating review is to address personalized multimodality systemic treatment for patients with metastatic cancer. The rationale for using high-dose RT is primarily for local control and immune activation in either oligometastatic or polymetastatic disease. However, the primary application of low-dose RT is to activate distinct antitumor immune pathways and modulate the tumor stroma in efforts to better facilitate T cell infiltration. We explore clinical cases involving high- and low-dose RT to demonstrate the potential efficacy of such treatment. We then group patients by extent of disease burden to implement high- and/or low-dose RT. Patients with low-volume disease may receive high-dose RT to all sites as part of an oligometastatic paradigm. Subjects with high-volume disease (for whom standard of care remains palliative RT only) could be treated with a combination of high-dose RT to a few sites for immune activation, while receiving low-dose RT to several remaining lesions to enhance systemic responses from high-dose RT and immunotherapy. We further discuss how emerging but speculative concepts such as immune function may be integrated into this approach and examine therapies currently under investigation that may help address immune deficiencies. The review concludes by addressing challenges in using RT for polymetastatic disease, such as concerns about treatment planning workflows, treatment times, dose constraints for multiple-isocenter treatments, and economic considerations.

View all citing articles on Scopus

^☆: A preliminary report was presented at the 20th Annual Meeting of the American Society of Therapeutic Radiologists, October 31–November 4, 1978, Los Angeles, California.

¹: American Cancer Society Clinical Oncology Fellow, 1978-79. Current Address: Department of Radiation Therapy, University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77030.

View full text

Original contributionThe palliation of hepatic metastases: Results of the radiation therapy oncology group pilot study☆

Abstract

Int. J. Radiat. Oncol. Biol. Phys.

Surg. Clinic N. Am.

Survival after liver resection for cancer

Cancer

Radiation hepatitis

Am. J. Roentgenol.

Factors influencing survival in patients with untreated hepatic metastases

Surg. Gynecol. Obstet.

Radiation hepatitis: Possible prevention by combined isotopic and external radiation therapy

Radiology

Experimental cancer chemotherapy

Original contribution
The palliation of hepatic metastases: Results of the radiation therapy oncology group pilot study☆